English
Email Chinese
25122017

I-Mab Biopharma signs licensing agreement for HyLeukin with Genexine

Genexine to receive an upfront payment and entitled to tiered, single-digit royalties on net sales of HyLeukin plus milestone payments from I-Mab Biopharma (I-Mab)....

1122017

I-Mab Biopharma and MorphoSys Partnership on Cancer Investigational Medicine

I-Mab and MorphoSys AG announced today that they have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao....

2242017

天境生物与药明生物达成战略合作

上海,2017年4月10日——中国生物药领先企业天境生物与药明康德关联公司药明生物签署战略合作协议。根据该协议,药明生物将为天境生物提供包括肿瘤免疫疗法及治疗自身免疫系统疾病的多个抗体类药物的临床前药学研究...

2232017

Official Website Online!

With all our efforts, Third Venture Biopharma's official website (in Chinese) was officially in public test phase on 21 March 2017. We hope that we can serve for our clients in a more prudent and professional manner....

2132017

Third Venture Biopharma and Tasgen Merge to form I-Mab, Raises $150m in Series B Financing

March 21st, 2017, Tianjin, China – Third Venture Biopharma, a company focusing on the discovery and development of the innovative biologics, and Tasgen Biotech, a clinical stage biologics development company focused on half-life extension bio-betters, announced today a definitive merger agreement to create a leading innovative biologics platform in China....

23122016

Third Venture Biopharma built strategic partnership with Ferring Pharmaceuticals

On 19 December 2016, Third Venture Biopharma built strategic partnership with Ferring Pharmaceuticals, under which, Third Venture Biopharma was granted the exclusive rights to develop and commercialize Olamkicept (an autoimmune drug of Ferring Pharmaceuticals) for autoimmune indications in Asia....

Home Previous Next End 1/1page  6 10/page To:

Address: Suite 802, West Tower, OmniVision, 88 Shangke Road, Pudong District, Shanghai, China, 201210    Tel:86-21-6057 8000     Email:marcom@i-mabbiopharma.com